|Reactivity||Human Mouse Rat|
|Tested applications||WB IHC|
|Recommended Dilution||WB 1:500 - 1:2000
IHC 1:50 - 1:200|
|Observed MW||Refer to Figures|
|Immunogen||Recombinant protein of human VEGFB|
|Storage Buffer||Store at -20℃. Avoid freeze / thaw cycles.
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.|
|Synonym||VEGFB; VEGFL; VRF; Vascular endothelial growth factor B; VEGF-related factor ;|
Western blot analysis of extracts of mouse heart cell lines, using VEGFB antibody.
Immunohistochemistry of paraffin-embedded human colon carcinoma using VEGFB antibody at dilution of 1:100 (400x lens).
Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells. VEGF and its close relatives VEGF-B, -C and -D form a subfamily within PDGF family of growth factors, which belongs to the cysteine knot class of cytokines. Five VEGF isoforms of 121, 145, 165, 189 and 206 amino acids (VEGF121–206) are generated as a result of alternative splicing from a single VEGF gene (1).The various VEGF forms bind to three tyrosine-kinase receptors, VEGFR-1, VEGFR-2 and VEGFR-3 which are expressed almost exclusively in endothelial cells. VEGFR-2 is the main angiogenic signal transducer for VEGF, while VEGFR-3 is specific for VEGF-C and -D and is necessary and sufficient for lymphangiogenic signaling. However, upon proteolytic processing VEGF-C and -D gain the ability to also bind and activate VEGFR-2 (2). Guided by the binding properties of the ligands, the VEGFRs are able to form both homodimers and heterodimers. Receptor dimerization is accompanied by activation of receptor kinase activity leading to receptor autophosphorylation. Phosphorylated receptors recruit interacting proteins and induce downstream signaling (3). Recently, tumor therapies based on neutralizing anti-VEGF antibodies and small molecule tyrosine kinase inhibitors targeting VEGFRs have been developed. These new strategies for tumor treatment show the clinical relevance of inhibiting VEGF signal transduction pathways that are exaggerated in pathological angiogenesis (4).
Neo Scientific welcomes feedback from its customers.
If you have used an our product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information.
If you have any additional inquiries please email technical services at email@example.com
Thank you for your support.